Kawasaki Disease Comparative Effectiveness (KIDCARE) Trial
John Manaloor, MD
Primary Investigator
Brief description of study
This study is being done to find out the best treatment for children with KD who have fever after standard treatment (IVIG plus aspirin). We call this condition ?IVIG resistance?.
Detailed description of study
The purpose of this study is to find out the best treatment for children with KD who have fever after standard treatment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Kawasaki Disease
-
Age: 1 years - 17 years
-
Gender: All
Inclusion Criteria
Kawasaki Disease
Have had fever for 3 to 10days prior to initial IVIG treatment
Have fever between 36 hours and 7 days after the end of first IVIG infusion without other likely cause
Exclusion Criteria
Patient treated with infliximab or steroids for present illness
Known prior infection with tuberculosis, coccidiomycosis, or histoplasmosis
Household member with active TB
Use of a TNFalpha blocker within the 3 months prior enrollment
Have any chronic disease, except asthma, atopic dermatitis, autism or controlled seizure disorder
Has a history of hypersensitivity to infliximab
